The first TGF-β signature was defined on the basis of a clinical trial with genes showing significant change in expression in skin biopsies from patients with SSc treated with anti-TGF-β monoclonal antibody (R = − 0.796,p < 0.0001) (Fig. 1d) [37]. The gene discussed is TGFB1; the disease is systemic sclerosis.